A Novel Azathioprine Polysaccharide Nanoparticle Enhances the Efficacy of Systemic Lupus Erythematosus Therapy

Systemic lupus erythematosus (SLE) patients will suffer from some level of discomfort as the disease progresses due to involvement with the respiratory system. Shrinking lung syndrome is an uncommon disease side effect. SLE has traditionally been treated with chemical immunosuppressants. But these chemical drugs have low solubility, a short half-life in circulation, poor solubility, and higher side effects. One of the most effective ways to extend the time of circulation is to combine pharmaceuticals with nanocarriers that are developed. This method is particularly interesting autoimmune disorders have not been widely employed for the treatment of cancer and other infectious diseases. Here, we use a novel biocompatible polysaccharide nanoparticle, effectively synthesizing a simple but universal drug delivery platform. The immunosuppressant azathioprine was initially conjugated onto the polysaccharide nanocarrier in this proof-of-concept trial for the treatment of SLE. The kidneys only cleared the AZA-PHA nanoparticles slowly, and they had a 30% cytotoxicity. Azathioprine-polysaccharide nanoparticles demonstrated greater therapeutic efficacy to azathioprine-polysaccharide nanoparticles in a murine SLE model without significantly increasing toxicity. This delivery method, which might act as a fresh and universal platform, might make it possible to treat SLE.